| Literature DB >> 34959817 |
Alexandra Bekiaridou1, Eleni Karlafti1, Ilias Marios Oikonomou1, Aristidis Ioannidis2, Theodossis S Papavramidis2.
Abstract
Skin tissue repair is of fundamental importance for maintaining homeostasis regulation, protection barrier, absorption, and excretion of skin tissue. Wound healing is a complicated process that can be impaired by infections and therefore have a significant economic and social impact. Simultaneously, the overuse of antibiotics has led to antimicrobial resistance and loss of their efficacy. Thus, the need for alternative antimicrobial agents is urgent. The newest approaches on wound dressings employ new therapeutic agents, such as probiotics. Probiotics alone or in tandem with nanotechnology-based techniques exhibit a broad range of benefits on surgical wounds. This systematic review aims to consider current knowledge of probiotic effects on animals and humans regarding surgical wound healing and provide new insights into the role of nanotechnology. The databases included were PubMed (MEDLINE), Scopus, and Cochrane Library (CENTRAL). Studies focused on burns, chronic wounds, and diabetic ulcers were excluded. The promising industry of probiotics demonstrates a significant upsurge as more and more healthy individuals rely their well-being on alternative medicine. Included probiotics illustrated positive results on wound re-epithelization, neovascularization, and wound healing. No adverse effects were noted.Entities:
Keywords: nanotechnology; probiotics; surgical wound healing; wound dressing
Mesh:
Substances:
Year: 2021 PMID: 34959817 PMCID: PMC8704946 DOI: 10.3390/nu13124265
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Detailed summary of human and animal studies included. All the outcomes noted are significantly different from the control groups applied in every study.
| Study | Year | Country | Target Area | Treatment | Probiotics Studied | Summary of Key Findings | Animal/ | Control |
|---|---|---|---|---|---|---|---|---|
| DiMarzio [ | 1999 | Italy | Forearm skin | Base cream as vehicle containing | Significantly increased skin stratum corneum ceramide levels | Human | Base cream | |
| DiMarzio [ | 2008 | Italy | Forearm skin | Base cream as vehicle containing | Increased skin ceramides | Human | Base cream | |
| Gan [ | 2002 | Canada | Surgical implants | Solutions with biosurfactant from | Significantly inhibited | Animal | Negative control group treated with PBS only | |
| Atalan [ | 2003 | Turkey | Wounds | Mixture of vaseline and kefir | Kefir | Enhanced wound healing | Animal | Mixture with vaseline |
| Rodriguez [ | 2005 | Brasil | Wounds | Kefir gel | Kefir with | Enhanced wound healing measured by size and histology | Animal | Negative control group treated with 0.9% NaCl |
| Halper [ | 2008 | Georgia | Wounds | Subcutaneous injection of lyophilized |
| Stimulated inflammatory stage of tissue repair, TNF-a production, and angiogenesis | Animal | Group treated phosphate- buffered saline in 2% methylcellulose |
| Zahedi [ | 2011 | Iran | Wounds | Ointment with 1010–1011 CFU/mL bacteria and eucerin |
| Significant reduction in inflammation | Animal | Untreated negative control group |
| Zahedi [ | 2011 | Iran | Wounds | Ointment with 1010–1011 CFU/mL bacteria and eucerin |
| Increased number of myofibroblasts | Animal | Untreated negative control group |
| David [ | 2011 | Nigeria | Surgical skin lesion | Gauze soaked in partially purified enterocin E3 | Enterocin E3 from | Enterocin E3 was effective against | Animal | Group treated with distilled water |
| Nasrabadi [ | 2011 | Iran | Full-thickness wound | Mixture of |
| Significant reduction in neutrophils, macrophages, and fibroblasts | Animal | Positive control treated with eucerin |
| Jones [ | 2012 | Canada | Infected wounds | gNO dressings with microbeads containing |
| Increased wound closure | Animal | Control patches with glucose (10% |
| Heunis [ | 2013 | South Africa | Infected wounds | Antimicrobial nanofiber wound dressing | Nisin | Maintained its antistreptococcal activity in vitro for at least 4 days | Animal | Nanofiber wound dressings without nisin |
| Van Staden [ | 2016 | South Africa | Infected wounds | Treatment with 12.5 μL (250 μM) of Amyloliquecidin, clausin, or nisin applied directly onto the wound | Nisin from | Significantly reduced the bioluminescence of | Animal | Mupirocin-based ointment |
| Zhu [ | 2017 | China | Two strains of bacteria ( | Mixture with 50 mL sodium acetate buffer solution, 1.0 g hydroxypropyl chitosan, 1.1 g nisin, 0.25 g of Microbial transglutaminase powder | Nisin | Antibacterial activity against | Animal | Hydroxypropyl chitosan blank control sample |
| Fu [ | 2017 | China | Mandibular Fracture | Injection containing bacteriocin | Bacteriocin isolated from | Bacteriocin could significantly reduce the formation of biofilms and inflammation factor | Animal | Group injected with 1 mL sterile saline solution |
| Fu [ | 2018 | China | Mandibular fracture | Injection containing bacteriocin | Bacteriocin from | Serum levels of TNF-a and CRP were significantly lower than in controls | Animal | Group injected with 1 mL sterile saline solution |
| Ong [ | 2019 | Malaysia | Full thickness wound | A 10% ( |
| Inhibited | Animal | Placebo-treated control group |
| Xu [ | 2019 | China | Infected femoral Fracture with Internal Fixation | Injection with tea polyphenols and bacteriocins | Bacteriocin from | Effectively controlled | Animal | Negative control treated with saline |
| Mouritzen [ | 2019 | Denmark | Wounds | Mixture of 25 μg/mL Nisin A, 100 ng/mL LPS, or a combination of Nisin A and LPS and incubated at 37 °C, 5% CO2 | Nisin A from | Dampened the effect of lipopolysaccharide and proinflammatory cytokines | Animal | Positive control were cells treated with free amino acids in the same mole-ratio as in Nisin A |
| Liu [ | 2020 | China | PEG-PCL-MP1 formula | MP1 from S. hominis S34-1 | Reduced | Animal | Negative control group MRSA- infected/PEG-PCL | |
| Cheleuitte-Nieves [ | 2020 | France | Infected cranial implant margins with MRSA | Liquid lysostaphin (5 mg/mL; total 3 mL/dose) applied topically | Bacteriocin lysostaphin | Decrease MRSA infection short-term, with no resistance discovered | Animal | Systemic administration of antibiotics |
| Qiao [ | 2020 | China | Wounds | Treatment with PBS, 1 × MIC BMP32r (27.6 mg/L) | BMP32r from | Promoted wound healing by killing the multidrug-resistant | Animal | Negative control group left untreated |
| Ovchinnikov [ | 2020 | Norway | Wounds | Mixture containing 5 mg/mL garvicin KS, 5 mg/mL Penicillin G, and 0.1 mg/mL MP1 in 5% hydroxypropyl cellulose | Bacteriocin garvicin KS and MP1 | Efficient in eradicating the MRSA from treated wounds | Animal | Group treated with Fucidin cream |
| Nam [ | 2021 | Korea | Wounds | 100 µL of heat-killed Lc. chungangensis CAU 1447 combined with a eucerin ointment | Beneficial effects on wound healing | Animal | Negative control group left untreated | |
| Ovchinnikov [ | 2021 | Norway | Wounds | MP1 (10 µg/mL) in base cream | MP1 | Synergistic effects against MRSA | Animal | Negative control left untreated |
Abbreviations: Enterocin E3, Enterococcus faecalis E3; L. Lactis, Lactobacillus Lactis; L. Brevis, Lactobacillus brevis; L. Plantarum, Lactobacillus plantarum; L. fermentum, Lactobacillus fermentum; L. Rhamnosus, Lactobacillus rhamnosus; MP1, Τhiopeptide bacteriocin micrococcin P1; PBS, phosphate-buffered saline; BMP32r, Bacteriocin BMP32r; E. coli, Escherichia coli; MRSA, Persistent methicillin-resistant S. aureus; PEG-PCL, glycol and polycaprolactone; Lc. Chungangensis, Lactococcus chungangensis.
Detailed summary of in vitro studies included. All the outcomes noted are significantly different from the control groups applied in every study.
| Study | Year | Country | Target Area | Treatment | Probiotics Studied | Summary of Key Findings | Control |
|---|---|---|---|---|---|---|---|
| DiMarzio [ | 1999 | Italy | Human keratinocyte cell line | Sonicated bacteria (1.7 g per 5 mL) mixed with 20 mL of a base cream | Increased ceramide levels | Base cream | |
| Pinto [ | 2011 | Italy | Human keratinocyte cells | Co-culture between | Plantaricin A synthesized by | Promoted wound re-epithelization and neo-vascularization | Basal serum free medium |
| Jiang [ | 2014 | China | Agar culture | Nisin-loaded phosphorylated soybean protein isolate/poly (l-lactic acid)/zirconium dioxide nanofibrous membranes | Nisin | Displayed well-controlled release and better antimicrobial activity against | Copper with no nanofibrous membrane |
| Ahire [ | 2015 | South Africa | Soft agar (1 % | Nanofibers with AgNPs and nisin [silver plus nisin nanofibers (SNF)] | Nisin | Inhibited the growth of gram-positive and gram-negative bacteria | Control nanofibers without AgNPs and nisin |
| Tavakolian [ | 2018 | Canada | Bacterial cells | Wound dressings with sterically stabilized nanocrystalline cellulose (SNCC), nisin or lysozyme | Lysozyme, nisin | Effectively inhibited the growth of planktonic | Unconjugated dressing with lysozyme and nisin SNCC |
| Mouritzen [ | 2019 | Denmark | Human keratinocyte cells | 25 μg/mL Nisin A | Nisin A | Increased the mobility of skin cells | Negative control were cells mixed with free amino acids |
| Twomey [ | 2020 | Twomey | Simulated wound fluid | Agar-based assays with nisin | Nisin A | Significantly reduced the amount of biofilm of | Assays without nisin |
| Peng [ | 2020 | China | Erythrocyte solution | Sodium-type deacylated G–nisin mixture | Nisin bonded with gellan gum (a biocompatible polysaccharide) | The gellan-nisin conjugate kept its antimicrobial properties even with heat alkali treatment at 80 °C or chymotrypsin digestion | Blank control samples without the antibacterial agents |
| Thapa [ | 2020 | Norway | Cultured fibroblast cells | Peptides diluted in solutions | Multi-peptide bacteriocin GarkS from | Increased overall cell proliferation | Untreated cells |
Abbreviations: S. aureus, Staphylococcus aureus; S. epidermidis, Staphylococcus epidermidis; GarKS, Garvicin KS.